Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (3787)	10/21/1999 2:42:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Mazen, I agree that an acquisition doesn't make sense at this point, given how much they already have on their plate and their comparatively depressed stock price. The market's reaction to MLNM's acquisition of LKST would also make anyone think twice. However, it is always smart to keep one's eyes wide open - there have been some bargains in the depths of the biotech 3rd tier, and it may always be possible to snap up something real cheap. As I mentioned once before, CELG would be a partial fit because of its Ritalin ICE, but the rest of the company isn't a great fit. It's also no longer quite as cheap as it was when I first mentioned it. Peter

To: M. Ramle who wrote (3787)	10/25/1999 11:17:00 AM
From: rkrw	Read Replies (1) \| Respond to of 10280

<<IMHO, I think that would be very foolish for the Management to even be considering any acquisitions at this time. They (SEPR) are NOT even out of the woods yet, and they need to rack up more interest in their own stock first. Any comments !!!! Thanks and Good Luck.>> M. The xopenex sales force, at least for the moment, is inefficient selling just one product, xopenex nebulizer. Their selling and marketing expenses last quarter were very high. In other words, they are losing money marketing xopenex and may well continue to do so through all of next year. If they can leverage the force against a second or third product, via acquisition, product acquisition, product purchase, quid, whatever, they could achieve greater sales efficiencies and downstream profitability. The alternative is to sit and wait for internally developed follow on products which are approximately 2-3 years away from market. Managements sole pursuit should be maximizing long term shareholder wealth not prioritizing the share price for the next few weeks. If a product acquisition arises that will benefit shareholders I'd hope it would be strongly considered.